[S-3ASR] Waste Management, Inc. SEC Filing
Ingersoll Rand (IR) Q2 2025 10-Q highlights
- Revenue rose 4.6% YoY to $1.89 B; YTD sales up 3.7% to $3.60 B.
- Non-cash impairments hit results: $229.7 M goodwill (Biopharma & Aerospace/Defense units) and $36.1 M tradename, cutting operating income 72% to $76.4 M and driving a $115 M GAAP net loss (-$0.29 EPS) versus $185 M profit a year ago.
- Core cost structure steady: gross margin 43.7% (-20 bp YoY); SG&A up 8.5% on acquisitions and inflation.
- Cash flow solid: $502 M operating cash YTD (+8%), funding $279 M capex/M&A and $510 M share buybacks; cash balance $1.31 B (-$231 M YTD).
- Balance-sheet metrics: long-term debt $4.78 B (flat), net debt/EBITDA still modest; equity $10.16 B.
- M&A momentum: five deals (SSI, Excelsior, Cullum & Brown, G&D Chillers, Lead Fluid) for $236.7 M widen flow-creation and life-science exposure; integration costs reflected in results.
- Currency translation gains trimmed accumulated OCI deficit by $328 M.
Key earnings quality issues: equity-method loss (-$121 M) and higher interest expense (+24%) further pressured bottom line. Ex-impairment, underlying profitability appears stable but management did not provide updated guidance within the filing.
Punti salienti del 10-Q del 2° trimestre 2025 di Ingersoll Rand (IR)
- I ricavi sono aumentati del 4,6% su base annua, raggiungendo 1,89 miliardi di dollari; le vendite da inizio anno sono cresciute del 3,7% a 3,60 miliardi di dollari.
- Le svalutazioni non monetarie hanno inciso sui risultati: 229,7 milioni di dollari di avviamento (unità Biopharma e Aerospace/Defense) e 36,1 milioni di dollari di marchi, riducendo l’utile operativo del 72% a 76,4 milioni di dollari e generando una perdita netta GAAP di 115 milioni di dollari (-0,29 dollari per azione) rispetto a un utile di 185 milioni dell’anno precedente.
- La struttura dei costi core è stabile: margine lordo al 43,7% (-20 punti base su base annua); spese SG&A in aumento dell’8,5% a causa di acquisizioni e inflazione.
- Flusso di cassa solido: 502 milioni di dollari di cassa operativa da inizio anno (+8%), utilizzati per finanziare 279 milioni di dollari in investimenti/M&A e 510 milioni di dollari in riacquisti di azioni; saldo di cassa 1,31 miliardi di dollari (-231 milioni da inizio anno).
- Indicatori patrimoniali: debito a lungo termine stabile a 4,78 miliardi di dollari, rapporto netto debito/EBITDA ancora contenuto; patrimonio netto 10,16 miliardi di dollari.
- Impulso M&A: cinque operazioni (SSI, Excelsior, Cullum & Brown, G&D Chillers, Lead Fluid) per 236,7 milioni di dollari ampliano la creazione di flussi e l’esposizione alle scienze della vita; i costi di integrazione sono riflessi nei risultati.
- I guadagni da traduzione valutaria hanno ridotto il deficit accumulato nell’OCI di 328 milioni di dollari.
Questioni chiave sulla qualità degli utili: la perdita da metodo del patrimonio netto (-121 milioni di dollari) e l’aumento degli oneri finanziari (+24%) hanno ulteriormente inciso sul risultato netto. Escluse le svalutazioni, la redditività sottostante sembra stabile, ma la direzione non ha fornito aggiornamenti sulle previsioni nel documento.
Aspectos destacados del 10-Q del 2T 2025 de Ingersoll Rand (IR)
- Los ingresos aumentaron un 4,6% interanual hasta 1,89 mil millones de dólares; las ventas acumuladas subieron un 3,7% hasta 3,60 mil millones de dólares.
- Las amortizaciones no monetarias afectaron los resultados: 229,7 millones de dólares en plusvalía (unidades Biopharma y Aerospace/Defense) y 36,1 millones de dólares en nombres comerciales, reduciendo el ingreso operativo un 72% a 76,4 millones de dólares y generando una pérdida neta GAAP de 115 millones de dólares (-0,29 dólares por acción) frente a una ganancia de 185 millones el año anterior.
- Estructura de costos principal estable: margen bruto del 43,7% (-20 puntos básicos interanual); gastos SG&A aumentaron un 8,5% debido a adquisiciones e inflación.
- Flujo de caja sólido: 502 millones de dólares de flujo operativo acumulado (+8%), financiando 279 millones de dólares en capex/M&A y 510 millones de dólares en recompras de acciones; saldo de caja 1,31 mil millones de dólares (-231 millones acumulados).
- Métricas del balance: deuda a largo plazo 4,78 mil millones de dólares (estable), deuda neta/EBITDA aún modesta; patrimonio neto 10,16 mil millones de dólares.
- Impulso en M&A: cinco acuerdos (SSI, Excelsior, Cullum & Brown, G&D Chillers, Lead Fluid) por 236,7 millones de dólares amplían la generación de flujo y la exposición a ciencias de la vida; costos de integración reflejados en resultados.
- Las ganancias por traducción de divisas redujeron el déficit acumulado en OCI en 328 millones de dólares.
Cuestiones clave sobre la calidad de las ganancias: la pérdida por método de participación (-121 millones de dólares) y el aumento de gastos por intereses (+24%) presionaron aún más el resultado final. Excluyendo las amortizaciones, la rentabilidad subyacente parece estable, pero la dirección no proporcionó una actualización de las previsiones en el informe.
Ingersoll Rand (IR) 2025년 2분기 10-Q 주요 내용
- 매출이 전년 동기 대비 4.6% 증가하여 18억 9천만 달러를 기록; 연초 이후 매출은 3.7% 증가한 36억 달러.
- 비현금성 손상차손 영향: 2억 2,970만 달러의 영업권(바이오파마 및 항공우주/국방 부문)과 3,610만 달러의 상표권 손상으로 영업이익이 72% 감소한 7,640만 달러에 그쳤으며, 1억 1,500만 달러 GAAP 순손실(주당순손실 -0.29달러)을 기록, 전년 동기 1억 8,500만 달러 이익과 대비됨.
- 핵심 비용 구조 안정적: 매출총이익률 43.7%(-20bp YoY); SG&A 비용은 인수 및 인플레이션 영향으로 8.5% 증가.
- 현금 흐름 견고: 연초 이후 5억 2천만 달러 영업 현금 흐름(+8%), 2억 7,900만 달러의 자본 지출/M&A 및 5억 1천만 달러의 자사주 매입에 사용; 현금 잔액은 13억 1천만 달러(연초 대비 -2억 3,100만 달러).
- 재무 지표: 장기 부채 47억 8천만 달러로 변동 없음, 순부채/EBITDA는 여전히 적정 수준; 자본 총계 101억 6천만 달러.
- M&A 모멘텀: SSI, Excelsior, Cullum & Brown, G&D Chillers, Lead Fluid 등 5건의 거래로 2억 3,670만 달러 규모, 현금 흐름 창출 및 생명과학 노출 확대; 통합 비용이 결과에 반영됨.
- 환율 변동에 따른 환산이익으로 누적 OCI 적자가 3억 2,800만 달러 감소.
주요 수익 품질 이슈: 지분법 손실(-1억 2,100만 달러)과 이자 비용 증가(+24%)가 순이익에 추가 압박을 가함. 손상차손을 제외하면 기본 수익성은 안정적이나 경영진은 보고서 내에서 업데이트된 가이던스를 제공하지 않음.
Faits saillants du 10-Q du 2e trimestre 2025 d’Ingersoll Rand (IR)
- Le chiffre d’affaires a augmenté de 4,6 % en glissement annuel pour atteindre 1,89 milliard de dollars ; les ventes cumulées depuis le début de l’année ont progressé de 3,7 % pour s’établir à 3,60 milliards de dollars.
- Des dépréciations non monétaires ont impacté les résultats : 229,7 millions de dollars d’écart d’acquisition (unités Biopharma et Aérospatial/Défense) et 36,1 millions de dollars de nom commercial, réduisant le résultat opérationnel de 72 % à 76,4 millions de dollars et entraînant une perte nette GAAP de 115 millions de dollars (-0,29 $ par action) contre un bénéfice de 185 millions un an auparavant.
- Structure des coûts de base stable : marge brute de 43,7 % (-20 points de base en glissement annuel) ; les frais SG&A ont augmenté de 8,5 % en raison des acquisitions et de l’inflation.
- Flux de trésorerie solide : 502 millions de dollars de trésorerie opérationnelle depuis le début de l’année (+8 %), finançant 279 millions de dollars en capex/F&A et 510 millions de dollars en rachats d’actions ; solde de trésorerie de 1,31 milliard de dollars (-231 millions depuis le début de l’année).
- Indicateurs du bilan : dette à long terme stable à 4,78 milliards de dollars, ratio dette nette/EBITDA toujours modéré ; capitaux propres 10,16 milliards de dollars.
- Élan M&A : cinq transactions (SSI, Excelsior, Cullum & Brown, G&D Chillers, Lead Fluid) pour 236,7 millions de dollars élargissent la génération de flux et l’exposition aux sciences de la vie ; les coûts d’intégration sont reflétés dans les résultats.
- Les gains de conversion de devises ont réduit le déficit OCI cumulé de 328 millions de dollars.
Principaux enjeux de la qualité des résultats : la perte selon la méthode de mise en équivalence (-121 millions de dollars) et la hausse des charges d’intérêts (+24 %) ont encore pesé sur le résultat net. Hors dépréciations, la rentabilité sous-jacente semble stable, mais la direction n’a pas fourni de mise à jour des prévisions dans le rapport.
Ingersoll Rand (IR) Q2 2025 10-Q Highlights
- Umsatz stieg im Jahresvergleich um 4,6 % auf 1,89 Mrd. USD; der Umsatz seit Jahresbeginn erhöhte sich um 3,7 % auf 3,60 Mrd. USD.
- Nicht zahlungswirksame Wertminderungen belasteten die Ergebnisse: 229,7 Mio. USD Firmenwert (Biopharma- und Luftfahrt-/Verteidigungseinheiten) und 36,1 Mio. USD Markenname, wodurch das Betriebsergebnis um 72 % auf 76,4 Mio. USD sank und ein GAAP-Nettogewinnverlust von 115 Mio. USD (-0,29 USD je Aktie) im Vergleich zu einem Gewinn von 185 Mio. USD im Vorjahr entstand.
- Kernkostenstruktur stabil: Bruttomarge 43,7 % (-20 Basispunkte im Jahresvergleich); SG&A stiegen um 8,5 % aufgrund von Akquisitionen und Inflation.
- Solider Cashflow: 502 Mio. USD operativer Cashflow seit Jahresbeginn (+8 %), Finanzierung von 279 Mio. USD Capex/M&A und 510 Mio. USD Aktienrückkäufen; Kassenbestand 1,31 Mrd. USD (-231 Mio. USD seit Jahresbeginn).
- Bilanzkennzahlen: Langfristige Schulden 4,78 Mrd. USD (stabil), Nettoverschuldung/EBITDA weiterhin moderat; Eigenkapital 10,16 Mrd. USD.
- M&A-Momentum: Fünf Deals (SSI, Excelsior, Cullum & Brown, G&D Chillers, Lead Fluid) im Wert von 236,7 Mio. USD erweitern Cashflow-Generierung und Life-Science-Exposure; Integrationskosten in den Ergebnissen berücksichtigt.
- Währungsumrechnungsgewinne reduzierten das kumulierte OCI-Defizit um 328 Mio. USD.
Wesentliche Qualitätsthemen der Gewinne: Verlust aus Equity-Methode (-121 Mio. USD) und höhere Zinsaufwendungen (+24 %) belasteten das Ergebnis zusätzlich. Ohne Wertminderungen erscheint die zugrundeliegende Profitabilität stabil, Management gab jedoch im Bericht keine aktualisierte Prognose ab.
- None.
- None.
Insights
TL;DR: Solid top-line and cash flow overshadowed by large goodwill write-downs, turning earnings negative; core operations steady but valuation sentiment may weaken.
Revenue momentum (≈5% YoY) and 44% gross margin show demand resilience, yet $266 M impairments linked to the 2024 ILC Dover buyout wiped two quarters of profit. Operating margin collapsed to 4.0%. Excluding one-offs, EBITDA looks roughly flat, implying underlying execution remains intact. Liquidity is ample with $1.3 B cash and modest net leverage; however, $510 M buybacks amid falling earnings raise capital-allocation questions. The write-downs suggest management overpaid for biotech and A&D assets, which may compress multiple. Near-term stock reaction likely negative, but cash generation supports longer-term flexibility.
TL;DR: Impairments are non-cash, leverage steady; coverage ratios dip yet remain investment-grade-compatible, keeping debt holders largely insulated.
Net debt stays around $3.47 B with no near-term maturities; interest expense at $63 M vs EBITDA ~$530 M (annualized post-impairment) keeps interest-coverage >8×. Revolver capacity unchanged and operating cash flow comfortably funds acquisitions and buybacks. Goodwill charges do not affect covenants. Credit risk therefore stable, though additional equity-method losses warrant monitoring.
Punti salienti del 10-Q del 2° trimestre 2025 di Ingersoll Rand (IR)
- I ricavi sono aumentati del 4,6% su base annua, raggiungendo 1,89 miliardi di dollari; le vendite da inizio anno sono cresciute del 3,7% a 3,60 miliardi di dollari.
- Le svalutazioni non monetarie hanno inciso sui risultati: 229,7 milioni di dollari di avviamento (unità Biopharma e Aerospace/Defense) e 36,1 milioni di dollari di marchi, riducendo l’utile operativo del 72% a 76,4 milioni di dollari e generando una perdita netta GAAP di 115 milioni di dollari (-0,29 dollari per azione) rispetto a un utile di 185 milioni dell’anno precedente.
- La struttura dei costi core è stabile: margine lordo al 43,7% (-20 punti base su base annua); spese SG&A in aumento dell’8,5% a causa di acquisizioni e inflazione.
- Flusso di cassa solido: 502 milioni di dollari di cassa operativa da inizio anno (+8%), utilizzati per finanziare 279 milioni di dollari in investimenti/M&A e 510 milioni di dollari in riacquisti di azioni; saldo di cassa 1,31 miliardi di dollari (-231 milioni da inizio anno).
- Indicatori patrimoniali: debito a lungo termine stabile a 4,78 miliardi di dollari, rapporto netto debito/EBITDA ancora contenuto; patrimonio netto 10,16 miliardi di dollari.
- Impulso M&A: cinque operazioni (SSI, Excelsior, Cullum & Brown, G&D Chillers, Lead Fluid) per 236,7 milioni di dollari ampliano la creazione di flussi e l’esposizione alle scienze della vita; i costi di integrazione sono riflessi nei risultati.
- I guadagni da traduzione valutaria hanno ridotto il deficit accumulato nell’OCI di 328 milioni di dollari.
Questioni chiave sulla qualità degli utili: la perdita da metodo del patrimonio netto (-121 milioni di dollari) e l’aumento degli oneri finanziari (+24%) hanno ulteriormente inciso sul risultato netto. Escluse le svalutazioni, la redditività sottostante sembra stabile, ma la direzione non ha fornito aggiornamenti sulle previsioni nel documento.
Aspectos destacados del 10-Q del 2T 2025 de Ingersoll Rand (IR)
- Los ingresos aumentaron un 4,6% interanual hasta 1,89 mil millones de dólares; las ventas acumuladas subieron un 3,7% hasta 3,60 mil millones de dólares.
- Las amortizaciones no monetarias afectaron los resultados: 229,7 millones de dólares en plusvalía (unidades Biopharma y Aerospace/Defense) y 36,1 millones de dólares en nombres comerciales, reduciendo el ingreso operativo un 72% a 76,4 millones de dólares y generando una pérdida neta GAAP de 115 millones de dólares (-0,29 dólares por acción) frente a una ganancia de 185 millones el año anterior.
- Estructura de costos principal estable: margen bruto del 43,7% (-20 puntos básicos interanual); gastos SG&A aumentaron un 8,5% debido a adquisiciones e inflación.
- Flujo de caja sólido: 502 millones de dólares de flujo operativo acumulado (+8%), financiando 279 millones de dólares en capex/M&A y 510 millones de dólares en recompras de acciones; saldo de caja 1,31 mil millones de dólares (-231 millones acumulados).
- Métricas del balance: deuda a largo plazo 4,78 mil millones de dólares (estable), deuda neta/EBITDA aún modesta; patrimonio neto 10,16 mil millones de dólares.
- Impulso en M&A: cinco acuerdos (SSI, Excelsior, Cullum & Brown, G&D Chillers, Lead Fluid) por 236,7 millones de dólares amplían la generación de flujo y la exposición a ciencias de la vida; costos de integración reflejados en resultados.
- Las ganancias por traducción de divisas redujeron el déficit acumulado en OCI en 328 millones de dólares.
Cuestiones clave sobre la calidad de las ganancias: la pérdida por método de participación (-121 millones de dólares) y el aumento de gastos por intereses (+24%) presionaron aún más el resultado final. Excluyendo las amortizaciones, la rentabilidad subyacente parece estable, pero la dirección no proporcionó una actualización de las previsiones en el informe.
Ingersoll Rand (IR) 2025년 2분기 10-Q 주요 내용
- 매출이 전년 동기 대비 4.6% 증가하여 18억 9천만 달러를 기록; 연초 이후 매출은 3.7% 증가한 36억 달러.
- 비현금성 손상차손 영향: 2억 2,970만 달러의 영업권(바이오파마 및 항공우주/국방 부문)과 3,610만 달러의 상표권 손상으로 영업이익이 72% 감소한 7,640만 달러에 그쳤으며, 1억 1,500만 달러 GAAP 순손실(주당순손실 -0.29달러)을 기록, 전년 동기 1억 8,500만 달러 이익과 대비됨.
- 핵심 비용 구조 안정적: 매출총이익률 43.7%(-20bp YoY); SG&A 비용은 인수 및 인플레이션 영향으로 8.5% 증가.
- 현금 흐름 견고: 연초 이후 5억 2천만 달러 영업 현금 흐름(+8%), 2억 7,900만 달러의 자본 지출/M&A 및 5억 1천만 달러의 자사주 매입에 사용; 현금 잔액은 13억 1천만 달러(연초 대비 -2억 3,100만 달러).
- 재무 지표: 장기 부채 47억 8천만 달러로 변동 없음, 순부채/EBITDA는 여전히 적정 수준; 자본 총계 101억 6천만 달러.
- M&A 모멘텀: SSI, Excelsior, Cullum & Brown, G&D Chillers, Lead Fluid 등 5건의 거래로 2억 3,670만 달러 규모, 현금 흐름 창출 및 생명과학 노출 확대; 통합 비용이 결과에 반영됨.
- 환율 변동에 따른 환산이익으로 누적 OCI 적자가 3억 2,800만 달러 감소.
주요 수익 품질 이슈: 지분법 손실(-1억 2,100만 달러)과 이자 비용 증가(+24%)가 순이익에 추가 압박을 가함. 손상차손을 제외하면 기본 수익성은 안정적이나 경영진은 보고서 내에서 업데이트된 가이던스를 제공하지 않음.
Faits saillants du 10-Q du 2e trimestre 2025 d’Ingersoll Rand (IR)
- Le chiffre d’affaires a augmenté de 4,6 % en glissement annuel pour atteindre 1,89 milliard de dollars ; les ventes cumulées depuis le début de l’année ont progressé de 3,7 % pour s’établir à 3,60 milliards de dollars.
- Des dépréciations non monétaires ont impacté les résultats : 229,7 millions de dollars d’écart d’acquisition (unités Biopharma et Aérospatial/Défense) et 36,1 millions de dollars de nom commercial, réduisant le résultat opérationnel de 72 % à 76,4 millions de dollars et entraînant une perte nette GAAP de 115 millions de dollars (-0,29 $ par action) contre un bénéfice de 185 millions un an auparavant.
- Structure des coûts de base stable : marge brute de 43,7 % (-20 points de base en glissement annuel) ; les frais SG&A ont augmenté de 8,5 % en raison des acquisitions et de l’inflation.
- Flux de trésorerie solide : 502 millions de dollars de trésorerie opérationnelle depuis le début de l’année (+8 %), finançant 279 millions de dollars en capex/F&A et 510 millions de dollars en rachats d’actions ; solde de trésorerie de 1,31 milliard de dollars (-231 millions depuis le début de l’année).
- Indicateurs du bilan : dette à long terme stable à 4,78 milliards de dollars, ratio dette nette/EBITDA toujours modéré ; capitaux propres 10,16 milliards de dollars.
- Élan M&A : cinq transactions (SSI, Excelsior, Cullum & Brown, G&D Chillers, Lead Fluid) pour 236,7 millions de dollars élargissent la génération de flux et l’exposition aux sciences de la vie ; les coûts d’intégration sont reflétés dans les résultats.
- Les gains de conversion de devises ont réduit le déficit OCI cumulé de 328 millions de dollars.
Principaux enjeux de la qualité des résultats : la perte selon la méthode de mise en équivalence (-121 millions de dollars) et la hausse des charges d’intérêts (+24 %) ont encore pesé sur le résultat net. Hors dépréciations, la rentabilité sous-jacente semble stable, mais la direction n’a pas fourni de mise à jour des prévisions dans le rapport.
Ingersoll Rand (IR) Q2 2025 10-Q Highlights
- Umsatz stieg im Jahresvergleich um 4,6 % auf 1,89 Mrd. USD; der Umsatz seit Jahresbeginn erhöhte sich um 3,7 % auf 3,60 Mrd. USD.
- Nicht zahlungswirksame Wertminderungen belasteten die Ergebnisse: 229,7 Mio. USD Firmenwert (Biopharma- und Luftfahrt-/Verteidigungseinheiten) und 36,1 Mio. USD Markenname, wodurch das Betriebsergebnis um 72 % auf 76,4 Mio. USD sank und ein GAAP-Nettogewinnverlust von 115 Mio. USD (-0,29 USD je Aktie) im Vergleich zu einem Gewinn von 185 Mio. USD im Vorjahr entstand.
- Kernkostenstruktur stabil: Bruttomarge 43,7 % (-20 Basispunkte im Jahresvergleich); SG&A stiegen um 8,5 % aufgrund von Akquisitionen und Inflation.
- Solider Cashflow: 502 Mio. USD operativer Cashflow seit Jahresbeginn (+8 %), Finanzierung von 279 Mio. USD Capex/M&A und 510 Mio. USD Aktienrückkäufen; Kassenbestand 1,31 Mrd. USD (-231 Mio. USD seit Jahresbeginn).
- Bilanzkennzahlen: Langfristige Schulden 4,78 Mrd. USD (stabil), Nettoverschuldung/EBITDA weiterhin moderat; Eigenkapital 10,16 Mrd. USD.
- M&A-Momentum: Fünf Deals (SSI, Excelsior, Cullum & Brown, G&D Chillers, Lead Fluid) im Wert von 236,7 Mio. USD erweitern Cashflow-Generierung und Life-Science-Exposure; Integrationskosten in den Ergebnissen berücksichtigt.
- Währungsumrechnungsgewinne reduzierten das kumulierte OCI-Defizit um 328 Mio. USD.
Wesentliche Qualitätsthemen der Gewinne: Verlust aus Equity-Methode (-121 Mio. USD) und höhere Zinsaufwendungen (+24 %) belasteten das Ergebnis zusätzlich. Ohne Wertminderungen erscheint die zugrundeliegende Profitabilität stabil, Management gab jedoch im Bericht keine aktualisierte Prognose ab.
SECURITIES AND EXCHANGE COMMISSION
UNDER
THE SECURITIES ACT OF 1933
|
Delaware
(State or other jurisdiction of
incorporation or organization) |
| |
73-1309529
(I.R.S. Employer
Identification Number) |
|
Houston, Texas 77002
(713) 512-6200
Chief Legal Officer
Waste Management, Inc.
800 Capitol Street, Suite 3000
Houston, Texas 77002
(713) 512-6200
|
Large accelerated filer
☒
|
| |
Accelerated filer
☐
|
| |
Non-accelerated filer
☐
|
| |
Smaller reporting company
☐
|
|
| | | | | | | | | |
Emerging growth company
☐
|
|
Exact Name of Additional Registrant as Specified in its Charter*
|
| |
State or Other
Jurisdiction of Incorporation or Organization |
| |
I.R.S. Employer
Identification Number |
| ||||||
Waste Management Holdings, Inc.
|
| | | | Delaware | | | | | | 36-2660763 | | |
![[MISSING IMAGE: lg_wmregist-4c.jpg]](https://www.sec.gov/Archives/edgar/data/0000823768/000110465925072735/lg_wmregist-4c.jpg)
COMMON STOCK
PREFERRED STOCK
WARRANTS
GUARANTEES
UNITS
|
Forward-Looking Statements
|
| | | | 1 | | |
|
About this Prospectus
|
| | | | 4 | | |
|
Incorporation of Certain Documents by Reference
|
| | | | 5 | | |
|
Where You Can Find More Information
|
| | | | 6 | | |
|
The Company
|
| | | | 7 | | |
|
Risk Factors
|
| | | | 7 | | |
|
Use of Proceeds
|
| | | | 8 | | |
|
Description of the Debt Securities
|
| | | | 9 | | |
|
Description of Guarantees
|
| | | | 17 | | |
|
Description of Capital Stock
|
| | | | 18 | | |
|
Description of Other Securities
|
| | | | 21 | | |
|
Plan of Distribution
|
| | | | 22 | | |
|
Selling Securityholders
|
| | | | 24 | | |
|
Legal Matters
|
| | | | 25 | | |
|
Experts
|
| | | | 25 | | |
SEC Filing (Our SEC File Number is 1-12154)
|
| |
Date Filed
|
|
Annual Report on Form 10-K for the year ended December 31, 2024
|
| |
February 19, 2025
|
|
Quarterly Report on Form 10-Q for the quarter ended March 31, 2025
|
| |
April 29, 2025
|
|
Quarterly Report on Form 10-Q for the quarter ended June 30, 2025
|
| |
July 29, 2025
|
|
Current Report on Form 8-K
|
| |
February 28, 2025
|
|
Current Report on Form 8-K
|
| |
May 14, 2025
|
|
Current Report on Form 8-K
|
| |
May 14, 2025
|
|
The portions of our proxy statement for our 2025 annual meeting of stockholders incorporated by reference in our Annual Report on Form 10-K for the year ended December 31, 2024
|
| |
April 1, 2025
|
|
Description of our common stock contained in our Registration Statement on Form 8-B, as updated by the description of our common stock included in Exhibit 4.6 to our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 19, 2025, together with any subsequent amendment or report filed for the purpose of updating such description
|
| |
July 13, 1995
|
|
800 Capitol Street, Suite 3000
Houston, Texas 77002
Attn: Corporate Secretary
(713) 512-6200
INFORMATION NOT REQUIRED IN PROSPECTUS
|
SEC registration fee
|
| | | $ | * | | |
|
Legal fees and expenses
|
| | | $ | + | | |
|
Accounting fees and expenses
|
| | | $ | + | | |
|
Printing fees and expenses
|
| | | $ | + | | |
|
Rating agency fees and expenses
|
| | | $ | + | | |
|
Trustee’s and transfer agent’s fees and expenses
|
| | | $ | + | | |
|
Miscellaneous
|
| | | $ | + | | |
|
Total
|
| | | $ | | | |
|
Exhibit
Number |
| |
Description
|
|
| 3.1 | | |
Fourth Restated Certificate of Incorporation of Waste Management, Inc. (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on May 17, 2024).
|
|
| 3.2 | | |
Amended and Restated By-laws of Waste Management, Inc. (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on November 6, 2023).
|
|
| 3.3 | | | Third Restated Certificate of Incorporation of Waste Management Holdings, Inc. (incorporated by reference to Exhibit 4.2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2014). | |
| 3.4 | | | Amended and Restated By-laws of Waste Management Holdings, Inc. (incorporated by reference to Exhibit 4.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014). | |
| 4.1 | | |
Specimen Stock Certificate of Waste Management, Inc. (incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 1998).
|
|
| 4.2 | | | Indenture for Subordinated Debt Securities dated February 1, 1997 among the Company and The Bank of New York Mellon Trust Company, N.A. (the current successor to Texas Commerce Bank National Association), as trustee (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on February 7, 1997). | |
|
Exhibit
Number |
| |
Description
|
|
| 4.3 | | | Indenture for Senior Debt Securities dated September 10, 1997 among the Company and The Bank of New York Mellon Trust Company, N.A. (the current successor to Texas Commerce Bank National Association), as trustee (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on September 24, 1997). | |
| 5.1 | | |
Legal Opinion of Courtney A. Tippy.
|
|
| 22.1 | | | Guarantor Subsidiary (incorporated by reference to Exhibit 22.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025). | |
| 23.1 | | |
Consent of Courtney A. Tippy (included in Exhibit 5.1).
|
|
| 23.2 | | |
Consent of Ernst & Young LLP.
|
|
| 24.1 | | |
Power of Attorney (included on the signature pages of this registration statement).
|
|
| 25.1 | | |
Statement of Eligibility of Trustee on Form T-1 with respect to the senior indenture.
|
|
| 25.2 | | |
Statement of Eligibility of Trustee on Form T-1 with respect to the subordinated indenture.
|
|
| 107 | | |
Filing Fees Table.
|
|
Chief Executive Officer
|
Signature
|
| |
Title
|
|
|
/s/ JAMES C. FISH, JR.
James C. Fish, Jr.
|
| |
Chief Executive Officer and Director
(Principal Executive Officer) |
|
|
/s/ DEVINA A. RANKIN
Devina A. Rankin
|
| |
Executive Vice President and Chief Financial Officer
(Principal Financial Officer) |
|
|
/s/ JOHN CARROLL
John Carroll
|
| |
Vice President and Chief Accounting Officer
(Principal Accounting Officer) |
|
|
/s/ THOMAS L. BENÉ
Thomas L. Bené
|
| |
Director
|
|
|
/s/ BRUCE E. CHINN
Bruce E. Chinn
|
| |
Director
|
|
|
/s/ ANDRÉS R. GLUSKI
Andrés R. Gluski
|
| |
Director
|
|
|
/s/ VICTORIA M. HOLT
Victoria M. Holt
|
| |
Director
|
|
|
/s/ KATHLEEN M. MAZZARELLA
Kathleen M. Mazzarella
|
| |
Chair of the Board and Director
|
|
|
Signature
|
| |
Title
|
|
|
/s/ SEAN E. MENKE
Sean E. Menke
|
| |
Director
|
|
|
/s/ WILLIAM B. PLUMMER
William B. Plummer
|
| |
Director
|
|
|
/s/ MARYROSE T. SYLVESTER
Maryrose T. Sylvester
|
| |
Director
|
|
|
Signature
|
| |
Title
|
|
|
/s/ MARK A. LOCKETT
Mark A. Lockett
|
| |
President
(Principal Executive Officer) |
|
|
/s/ JOHN CARROLL
John Carroll
|
| |
Vice President, Chief Financial Officer and Controller
(Principal Financial Officer and Principal Accounting Officer) |
|
|
/s/ COURTNEY A. TIPPY
Courtney A. Tippy
|
| |
Director
|
|